stockrow
Friday 6 November 2026
Export RCEL’s income statement to Excel — free account
Avita Medical Inc.
RCEL Healthcare Medical Devices
Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024.
- Revenue
- +53.1%
- EPS
- +56.9%
- Free cash flow
- +86.7%
- Total debt
- +7.13%
Quarter to September 2026, against a year earlier
16.56
0.88
+5.61%
Follow RCEL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.28 | 1.68 | 1.56 | 1.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(509.94) | (36.33) | (11.22) | (17.68) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.24 | 2.70 | 2.58 | 2.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(22.50) | (8.42) | (6.02) | (5.21) | |
EV/FCF |
(22.07) | (8.02) | (5.72) | (4.92) | |
Quick Ratio |
0.90 | 0.31 | 0.36 | 0.44 | |
Current Ratio |
1.20 | 0.41 | 0.47 | 0.57 | |
Net Debt/EBITDA |
(8.54) | (6.39) | (3.72) | (2.56) | |
Debt/Assets |
97.18% | 97.66% | 89.51% | 76.22% | |
Debt/Equity |
(1.47) | (1.68) | (1.99) | (2.58) | |
Asset Turnover |
1.53 | 1.43 | 1.19 | 1.05 | |
Operating CF/Net income |
0.11 | 0.46 | 0.95 | 0.47 | |
Capex/Depreciation |
(0.19) | (0.18) | (0.03) | 0.06 | |
Interest Coverage |
(3.17) | (4.22) | (6.46) | (8.30) | |
Research and Development Expense of Revenue |
17.99% | 23.40% | 29.24% | 32.30% | |
Selling, General and Administrative Expense of Revenue |
76.10% | 90.06% | 98.19% | 108.01% | |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
6.39% | 9.16% | 5.72% | 7.79% | |
Graham Net Nets |
(0.14) | (0.37) | (0.38) | (0.39) | |
Graham Number |
5.15 | 5.41 | 5.17 | 4.84 | |
Earnings Yield |
(9.99%) | (34.78%) | (42.26%) | (50.55%) | |
Free Cash Flow Yield |
(5.55%) | (20.03%) | (28.84%) | (34.36%) | |
Revenue per Share |
0.85 | 0.71 | 0.63 | 0.63 | |
Operating CF per Share |
(0.02) | (0.11) | (0.33) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.12) | (0.33) | (0.19) | |
Cash per Share |
0.34 | 0.36 | 0.47 | 0.65 | |
Shareholders Equity per Share |
(1.01) | (0.91) | (0.76) | (0.60) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.01) | (0.91) | (0.76) | (0.60) | |
Free Cash Flow |
(0.82) | (3.60) | (10.09) | (5.40) | |
Working Capital |
4.64 | (40.32) | (35.02) | (27.19) | |
Capital Expenditures |
(0.11) | (0.11) | (0.02) | 0.04 | |
Net Current Asset Value |
(50.15) | (47.22) | (43.06) | (37.55) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.68 | 10.61 | 10.97 | 10.44 | |
Average Payables |
6.47 | 6.85 | 7.95 | 7.63 | |
Average Inventory |
6.02 | 6.41 | 7.26 | 7.10 | |
Average Assets |
55.26 | 52.96 | 60.55 | 68.05 | |
Average Common Equity |
(18.85) | (20.36) | (13.87) | (6.08) |
Columns are period end dates · fundamentals updated 5 Nov 2026